Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12495117 | 1.00 | CA2 (0.54) | CA2KDM4EALDH1A1HPGDKLK7 | |
| SCHEMBL15545264 | 0.85 | KDM4E (0.41) | CA2KDM4EALDH1A1HPGDKLK7 | |
| SCHEMBL3352223 | 0.85 | KDM4E (0.41) | CA2KDM4EALDH1A1HPGDKLK7 | |
| SCHEMBL3380580 | 0.85 | KDM4E (0.41) | CA2KDM4EALDH1A1HPGDKLK7 | |
| SCHEMBL9739615 | 0.79 | CA2 (0.48) | CA2 | |
| SCHEMBL3930475 | 0.79 | CA2 (0.45) | CA2 | |
| SCHEMBL9429618 | 0.78 | CA2 (0.43) | CA2 | |
| SCHEMBL9429518 | 0.78 | CA2 (0.43) | CA2 | |
| SCHEMBL9429738 | 0.78 | CA2 (0.43) | CA2 | |
| SCHEMBL18193400 | 0.76 | KDM4E (0.46) | KDM4EALDH1A1HPGDKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481686-B2 | Process for preparing enantiomerically enriched oxamides | ZACH SYSTEM S.P.A. (IT) | 2016-11-01 | — | — | US | disclosed |
| US-9481686-B2 | Process for preparing enantiomerically enriched oxamides | ZACH SYSTEM S.P.A. (IT) | 2016-11-01 | — | — | US | disclosed |
| US-20150191485-A1 | Process for Preparing Enantiomerically Enriched Oxamides | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2015-07-09 | — | — | US | disclosed |
| US-20150191485-A1 | Process for Preparing Enantiomerically Enriched Oxamides | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2015-07-09 | — | — | US | disclosed |
| WO-2014005943-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED OXAMIDES | ZACH SYSTEM S.P.A. (IT) | 2014-01-09 | — | — | WO | disclosed |
| US-8263787-B2 | Process for preparing dorzolamide | CIPLA LIMITED (IN) | 2012-09-11 | — | — | US | disclosed |
| WO-2011101704-A1 | PROCESS FOR PREPARING (4S, 6S)-4-(ETHYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO-[2,3-B]THIOPYRAN-2-SULFONAMIDE-7,7-DIOXIDE AND ITS INTERMEDIATES | MICRO LABS LIMITED (IN) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101704-A1 | PROCESS FOR PREPARING (4S, 6S)-4-(ETHYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO-[2,3-B]THIOPYRAN-2-SULFONAMIDE-7,7-DIOXIDE AND ITS INTERMEDIATES | MICRO LABS LIMITED (IN) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010061398-A1 | PROCESS FOR PREPARING DORZOLAMIDE HYDROCHLORIDE AND ITS INTERMEDIATE | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113804-A1 | Process for Preparing Dorzolamide | CIPLA LIMITED (IN) | 2010-05-06 | — | — | US | disclosed |
| WO-2008135770-A2 | PROCESS FOR PREPARING DORZOLAM IDE | CIPLA LIMITED (IN) | 2008-11-13 | — | — | WO | disclosed |
| EP-0296879-B1 | SUBSTITUTED AROMATIC SULFONAMIDES AS ANTIGLAUCOMA AGENTS | MERCK & CO. INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| US-4863922-A | Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use | MERCK & CO., INC. (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0296879-A1 | Substituted aromatic sulfonamides as antiglaucoma agents | MERCK & CO. INC. (US) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191485-A1 | Process for Preparing Enantiomerically Enriched Oxamides | OTC, CYP11B2, QDPR | CA2 162/4885KDM4E 1730/4885ALDH1A1 238/4885 |
| US-20100113804-A1 | Process for Preparing Dorzolamide | SQOR, PPOX, DAO | CA2 605/4885KDM4E 2357/4885ALDH1A1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.